CML Highlights of EHA 2024 – Clinical overview

Professor Andreas Hochhaus
Director of the Department of Hematology and Medical Oncology
Jena University Hospital (Germany)

00:00 Welcome and introduction
02:01 Treatment optimisation in CML (Hochhaus EHA 2024)
03:25 Line-agnostic treatment recommendations according to clinical and biological data
04:38 Asciminib first-line ASC4 First (Hochhaus et al, EHA 2024)
09:21 Dasatinib dose optimisation – DasaHit (La Rosée P et al., EHA 2024)
12:30 Ponatinib dose optimisation – OPTIC (Apperley J et al., EHA 2024)
14:21 Ponatinib and azacytidine in myeloid blast phase (Rousselot P et al., EHA 2024)

Q&A Session can be found at the end of the biological overview: